AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04467073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online RIT
Description: Online RIT presents RIT techniques in four sequential learning modules: (1) Setting Up For Success (2) Imitating your Child (3) Describing Play (4) Teaching Object Imitation. Each learning module includes an instructional video, quiz, interactive exercises, and at-home planning and reflection. The website also includes a video library, Frequently Asked Questions, downloadable visual aids, links to relevant external resources, and a customizable dashboard that allows users to track their individualized goals and the amount of time they have spent working on their goals (e.g., practice log).
Study NCT00602563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AMP
Description: The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
Study NCT04306614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration
Description: Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
Study NCT00602563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Relaxation (AR)
Description: Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev \& Chambless, 2007)
Study NCT00602563 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Monitoring (CM)
Description: participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
Study NCT00602563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combining the AMP and AR
Description: The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
Study NCT04306614 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endobronchial Ultrasound guided Transbronchial Fine Needle Aspiration
Description: Bronchoscopic procedure to allow for sampling mediastinal lymphadenopathy or proximal lung tumours under real-time ultrasound guidance.
Study NCT01489319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Study NCT01489319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: 4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
Study NCT00956059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone, FK506, MMF
Description: 1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4\~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6\~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
Study NCT00956059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: In the initial 16\~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
Study NCT02246049 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02246049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given IV
Study NCT02891408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firsocostat
Description: Capsule(s) administered orally on Day 1
Study NCT02891408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tablet administered orally on Day 1
Study NCT02246049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV
Study NCT02246049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Given IV
Study NCT02246049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01865422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent-proxy QoL chronic cough specific questionnaire (PC-QOL)
Study NCT00558246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Protape (Prineo)
Description: cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
Study NCT00558246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Topical Suturing
Study NCT01572181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
Description: * IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).
Study NCT00701454 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02322281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Study NCT02322281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed or gemcitabine or paclitaxel or docetaxel
Study NCT02478710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized Tobramycin or Vancomycin
Description: Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
Study NCT02478710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized Placebo
Description: Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
Study NCT03474614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
Study NCT03474614 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: DNA and RNA Analysis
Description: During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
Study NCT03474614 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA and RNA Analysis
Description: During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Oral tablets
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral capsule
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral tablets
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous Injection (single use vial)
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Intravenous Infusion
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Intravenous infusion
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Oral capsule
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Intravenous infusion
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Tablets
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Intravenous infusion
Study NCT02343042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Oral Capsules
Study NCT02785848 — intervention group
Intervention type: OTHER
Intervention: Interviews and Surveys
Description: The investigators will perform semi-structured interviews and surveys on this cohort
Study NCT05459467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks high intensity exercise programme
Study NCT06227871 — intervention group
Intervention type: PROCEDURE
Intervention: Exploratory laparotomy
Description: Exploratory laparotomy with interventions addressing pancreatic injuries Grade 1-5 including pancreatic interventions including subtotal pancreatectomy, distal pancreatectomy, pancreatic ligation, pyloric diversion, or simple drainage of the pancreas.
Study NCT04516720 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Diagnostic data : date and description of first symptoms,date of radiological diagnosis, tumor localization, number of lesions, date of histological diagnosis, histological diagnostic mode, histological diagnosis, WHO grade (I, II, III or IV), immunohistochemic data, molecular alterations therapeutic sequence : type of treatment, baseline exam before each treatment, surgery, radiothérapy, systemic treatment, clinical study, follow up until death
Study NCT00447720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
Study NCT00447720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PATH
Description: We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
Study NCT01500772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study NCT01500772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01500772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT04453865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project EMPOWER
Description: Project EMPOWER is a web-based, self-administered SSI for parents that takes about 30 minutes to complete
Study NCT04453865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Online Resources and Referrals
Description: Information sheet containing materials about the nature of child anxiety and a list of national resources related anxiety treatment.
Study NCT02531217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study NCT01227798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon alfacon-1
Description: 15 mcg at fill volume of 0.5mL
Study NCT01227798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT03282461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
Study NCT00537602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Study NCT00537602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02926872 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in the study
Study NCT01360671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
Study NCT04365972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: A home-delivered version of ABM will be administered in this open trial. ABM will be comprised of 5 sessions with a variation of the dot-probe task in which the target probe always replaces the neutral stimuli to induce diversion of attention away from threat. This condition was found effective in reducing anxiety symptoms.
Study NCT03361085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nvHAP Prevention Bundle
Description: oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
Study NCT03025425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy 100 ® (Philips Respironics)
Description: Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
Study NCT01378559 — intervention group
Intervention type: OTHER
Intervention: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire
Description: A questionnaire accessing satisfaction with a penis prosthesis
Study NCT03243851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide+Metformin
Description: Low dose temozolomide+metformin for 24 weeks
Study NCT03243851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide+Placebo
Description: Low dose temozolomide+placebo for 24 weeks
Study NCT01361022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lendormin tablet
Description: Lendormin tablet 250mc is administrated and compared
Study NCT01361022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam tablet
Description: Brotizolam tablet 250mc is administrated and compared
Study NCT06159452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study NCT06159452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR153191-P2 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study NCT06159452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAR153191-C1F3 drug product
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study NCT03153774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of sarcopenia prevalence
Description: Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
Study NCT03217344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: immobilization on sling of the injured arm
Study NCT03037073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 35 patients will receive duloxetine (Cymbalta; Eli Lilly \& Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
Study NCT03037073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
Study NCT02595983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revusiran
Description: 500mg Revusiran by subcutaneous (sc) injection
Study NCT00097500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
Study NCT00097500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
Study NCT00097500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients usual dosage
Study NCT00097500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients usual dosage
Study NCT01600885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Study NCT01600885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Study NCT00639197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: To tunnel
Description: Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
Study NCT00639197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard (not to tunnel)
Description: Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
Study NCT04616755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measuring changes of Little´s irregularity index ( sum of 5 contact point discrepancies together) measured in mm 2 years after retention have been I place.
Description: Measuring changes occurred under 2 years which the retention devices have been in place between the groups
Study NCT02538744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.